CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Mabvax Therapeutics Holdings Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Mabvax Therapeutics Holdings Inc
11588 SORRENTO VALLEY ROAD, SUITE 20
Phone: (858) 259-9405p:858 259-9405 SAN DIEGO, CA  92121  United States

This company ceased filing statements with the SEC on 3/29/2019.
The Company’s Plan of Liquidation went into effect on 3/20/2020
On 9/19/2019, the Company filed a Registration Withdrawal Request of its Form S-1 (File No. 333- 228497) with the SEC, initially filed with the Commission on November 20, 2018.
This company is no longer actively traded on any major stock exchange.

Business Summary
MabVax Therapeutics Holdings, Inc. is a clinical-stage biotechnology company with a fully human antibody discovery platform. The Company is focused on the translation into clinical development of products to address the medical needs in the treatment of cancer and pancreatitis. The Company discovered a pipeline of human monoclonal antibody product candidates based on the immune responses generated by patients. The Company's product pipeline includes ImmunoPET Imaging (MVT-2163) and Radioimmunotherapy (MVT-1075). MVT-2163 is an imaging agent for pancreatic cancer. MVT-1075 is a radioimmunotherapy for pancreatic cancer.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/201812/31/2017YesYes--Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board, President, Chief Executive Officer John D.Hansen 69 4/1/2015 7/8/2014
Chief Financial Officer Gregory P.Hanson 74 7/8/2014 7/8/2014
Chief Science Officer, Director Philip O.Livingston 78 7/8/2014 7/8/2014
6 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
MabVax Therapeutics, Inc. 11535 Sorrento Valley Road San Diego CA United States

Business Names
Business Name
MabVax Therapeutics, Inc.
MBVX
Telik, Inc.

General Information
Number of Employees: 22 (As of 2/15/2012)
Outstanding Shares: 9,429,582 (As of 4/24/2019)
Shareholders: 75
Stock Exchange: NASD
Federal Tax Id: 930987903
Email Address: INQUIRY@TELIK.COM


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023